Article
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2023
Yang Sheng, Wu Shiman, Zhao Yanqiu, Chen Gongyan, Zhu Bo, Li Xingya, Wang Ke, Shi Jianhua, Cang Shundong, Yao Wenxiu, Fan Yun, Fang Jian, Zhang Liangming, Zhou Jianying, Wu Lin, Zheng Rongsheng, Huang Meijuan, Pan Yueyin, Yang Zhixiong, Sun Meili, Yu Huiqing, Wang Donglin, Huang Jianan, Wang Lijun, Shu Yongqian, Chen Zhaohong, Liu Chunling, Li Jingzhang, Liu Jiwei, Sun Shenghua, Guo Yanzhen, Meng Zili, Liu Zhefeng, Han Zhigang, Wu Gang, Lu Hong, Ma Rui, Hu Sheng, Zhao Guofang, Zhang Longzhen, Liu Zheng, Xie Congying, Zhong Diansheng, Zhao Hui, Bi Minghong, Yi Shanyong, Guo Shuliang, Yi Tienan, Li Wen, Lin Yingcheng, Chen Zhendong, Zhuang Zhixiang, Guo Zhongliang, Greco Michael, Wang Tingting, Zhou Anqi, Shi Yuankai
Abstract excerpt
BACKGROUND: Rezivertinib (BPI-7711) is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) which revealed the systematic and central nervous system (CNS) antitumor activities for EGFR T790M-mutated advanced NSCLC in previous clinical studies and is further analyzed here. METHODS: Eligible patients from the previous phase I and phase IIb studies of rezivertinib were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.